Automate Your Wheel Strategy on JNJ
With Tiblio's Option Bot, you can configure your own wheel strategy including JNJ - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol JNJ
- Rev/Share 37.1342
- Book/Share 32.4693
- PB 4.73
- Debt/Equity 0.669
- CurrentRatio 1.2574
- ROIC 0.1201
- MktCap 369524230600.0
- FreeCF/Share 7.7211
- PFCF 19.8947
- PE 16.9397
- Debt/Assets 0.2698
- DivYield 0.0327
- ROE 0.2995
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | JNJ | Leerink Partners | Outperform | Market Perform | -- | $153 | May 13, 2025 |
| Resumed | JNJ | BofA Securities | -- | Neutral | -- | $166 | Dec. 10, 2024 |
News
Lilly, J&J boosted spending on executive security after UnitedHealth shooting
Published: March 12, 2025 by: Reuters
Sentiment: Neutral
U.S. drugmakers Johnson & Johnson and Eli Lilly increased spending on security for their top executives in 2024, with both citing increased threats after a UnitedHealth insurance executive was murdered outside the company's investor meeting in December, regulatory filings show.
Read More
ChatGPT picks 3 safe haven stocks to buy for 2025
Published: March 12, 2025 by: Finbold
Sentiment: Positive
The advent of artificial intelligence (AI) and machine learning has, in many ways, revolutionized the financial markets.
Read More
Cramer's Mad Dash: Johnson & Johnson
Published: March 11, 2025 by: CNBC Television
Sentiment: Neutral
Jim Cramer breaks down why he's keeping an eye on shares of Johnson & Johnson.
Read More
3 Dividend Stocks Set to Provide Stability in Market Chaos
Published: March 10, 2025 by: 24/7 Wall Street
Sentiment: Positive
Investors were in growth mode in the last two years as the stock market delivered blockbuster returns.
Read More
JNJ Halts Development of Depression Drug Over Efficacy Concerns
Published: March 07, 2025 by: Zacks Investment Research
Sentiment: Negative
While J&J is yet to give up on aticaprant, it decides to stop developing the drug for major depressive disorder due to a lack of sufficient efficacy.
Read More
Pfizer Vs. Johnson & Johnson: Who's The Better Bargain For Investors
Published: March 07, 2025 by: Seeking Alpha
Sentiment: Neutral
Johnson & Johnson and Pfizer occupy leading positions in the healthcare sector. Each of them has advantages, as well as dark spots in the portfolio of drugs relative to the comparator. In this article you will find out who is more promising for long-term investors.
Read More
Buy Johnson & Johnson (JNJ) Stock for Higher Highs?
Published: March 04, 2025 by: Zacks Investment Research
Sentiment: Negative
Amid recent market volatility, Johnson & Johnson (JNJ) stock hit new 52-week highs of nearly $170 on Tuesday.
Read More
Johnson & Johnson (JNJ) Could Be a Great Choice
Published: February 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
Read More
Johnson & Johnson (JNJ) Ascends While Market Falls: Some Facts to Note
Published: February 25, 2025 by: Zacks Investment Research
Sentiment: Neutral
In the closing of the recent trading day, Johnson & Johnson (JNJ) stood at $166.09, denoting a +1.44% change from the preceding trading day.
Read More
INTRA-CELLULAR THERAPIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intra-Cellular Therapies, Inc. - ITCI
Published: February 25, 2025 by: Business Wire
Sentiment: Neutral
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Intra-Cellular Therapies, Inc. (NasdaqGS: ITCI) to Johnson & Johnson (NYSE: JNJ). Under the terms of the proposed transaction, shareholders of Intra-Cellular will receive $132.00 in cash for each share of Intra-Cellular that they own. KSF is seeking to determine whether this consideration and the process t.
Read More
J&J sues Samsung Bioepis over contract breach for Stelara biosimilar
Published: February 24, 2025 by: Reuters
Sentiment: Negative
Johnson & Johnson said on Monday it had filed a lawsuit against Samsung Bioepis for breaching its contract agreement with the drugmaker over the launch of a biosimilar to Stelara, J&J's autoimmune drug.
Read More
Johnson & Johnson (JNJ) Up 8.9% Since Last Earnings Report: Can It Continue?
Published: February 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock?
Read More
Johnson & Johnson (JNJ) Laps the Stock Market: Here's Why
Published: February 19, 2025 by: Zacks Investment Research
Sentiment: Neutral
The latest trading day saw Johnson & Johnson (JNJ) settling at $157.89, representing a +1.87% change from its previous close.
Read More
Genmab: Positive 2025 Outlook, Johnson & Johnson's Decision Coming Soon
Published: February 18, 2025 by: Seeking Alpha
Sentiment: Positive
Genmab reported strong Q4 2024 results, with $897.4 million in revenue, beating expectations and showing 29% Y/Y growth, driven by Darzalex royalties. 2025 revenue guidance was slightly ahead of consensus and expense guidance was surprisingly low, indicating only 7% growth, and enhancing the company's financial outlook. J&J's decision on GEN3014 is pending; I expect J&J to opt out, but remain bullish on Genmab's product portfolio, pipeline, and growth prospects.
Read More
Johnson & Johnson: Rich History Of Excellence Poised To Endure
Published: February 18, 2025 by: Seeking Alpha
Sentiment: Positive
Johnson & Johnson offers a compelling balance of growth, innovation, and shareholder returns. JNJ's robust financials, including a fortress-like balance sheet and consistent dividends, support its ability to drive growth and innovation. The company is well-diversified across thriving healthcare segments, with promising FDA approvals and strategic M&A initiatives enhancing its market position.
Read More
J&J Stock Up More Than 6% in a Month: Time to Buy, Sell or Hold?
Published: February 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Those who own JNJ stock may stay invested for some time as the company looks optimistic about a better performance in 2025.
Read More
Johnson & Johnson halts late-stage E.coli vaccine trial after poor results
Published: February 13, 2025 by: New York Post
Sentiment: Negative
Johnson & Johnson and Sanofi said that while the vaccine showed no safety concerns, it did not meet the necessary effectiveness thresholds.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Johnson & Johnson - JNJ
Published: February 11, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Feb. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Johnson & Johnson. ("J&J" or the "Company") (NYSE: JNJ).
Read More
About Johnson & Johnson (JNJ)
- IPO Date 1943-01-02
- Website https://www.jnj.com
- Industry Drug Manufacturers - General
- CEO Mr. Joaquin Duato
- Employees 138100